Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2008-02-06
2011-11-15
Gonzalez, Porfirio Nazario (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C514S502000
Reexamination Certificate
active
08058462
ABSTRACT:
Ligand-modified poly oxo-hydroxy metal ion materials and their uses are disclosed, in particular for nutritional, medical, cosmetic or biologically related applications for example for the treatment of a deficiency related to a component of the material or for the removal of an endogenous substance capable of binding to the material. The present invention further relates to processes for preparing the materials and optimising their physico-chemical properties and their medical uses.
REFERENCES:
patent: 2575347 (1951-11-01), Kumins et al.
patent: 3076798 (1963-02-01), Mueller et al.
patent: 3679377 (1972-07-01), Young et al.
patent: 3821192 (1974-06-01), Montgomery et al.
patent: 4137359 (1979-01-01), Bak et al.
patent: 4162986 (1979-07-01), Alkaitis et al.
patent: 5514281 (1996-05-01), Boos et al.
patent: 7943664 (2011-05-01), Powell et al.
patent: 2003/0049284 (2003-03-01), Boccio et al.
patent: 2003/0181320 (2003-09-01), Rose et al.
patent: 2005/0209187 (2005-09-01), Newton et al.
patent: 2005/0209322 (2005-09-01), Rangisetty et al.
patent: 2006/0205691 (2006-09-01), Geisser et al.
patent: 2010/0032374 (2010-02-01), Powell et al.
patent: 20 2005 014 332 (2006-02-01), None
patent: 959282 (1964-08-01), None
patent: 1600449 (1981-10-01), None
patent: 264270 (1964-06-01), None
patent: 03031635 (2003-04-01), None
patent: 03092674 (2003-11-01), None
patent: 03097627 (2003-11-01), None
patent: 2004050031 (2004-06-01), None
patent: 2004074444 (2004-09-01), None
patent: 2004074444 (2004-09-01), None
patent: 2005000210 (2005-01-01), None
patent: 2006037449 (2006-04-01), None
patent: 2008096130 (2008-08-01), None
patent: 2009062993 (2009-05-01), None
Y. Maeda et al., “Correlation between Detrapped Valence States and Molecular Packing of Mixed-Valence Dinuclear Iron (II,III) Complexes of a Septadentate Polypyridine Ligand”, Chemistry Letters, 1:65-66 (1995).
R.B. Lanjewar et al., “Quadrupole Hyperfine Interaction in Iron (III) Dicarboxylic Acid Complexes”, J. Radioanalytical and Nuclear Chemistry, 125(1): 75-84 (1988).
Z. Smekal et al., “Binuclear iron (III)-iron (III) complexes with the tetradentate Schiff base, N,N′-bis(salicylidene) ethylenediamine and dicarboxylic acids or dithiooxamide as bridging ligands”, Transition Met. Chem., 21: 49-51 (1996).
C.L. Sharma et al., Mossbauer Studies on Some Penta Coordinated Mixed Ligand Complexes of Iron (III), Chemica Scripta, 18(3): 133-134 (1981).
M. Bobtelsky et al., “The Structure and Behavior of Ferric Tartrate and Citrate Complexes in Dilute Solutions”, Journal of the American Chemical Society, 69: 2286-2290 (1947).
V.R. Edgerton et al., “Iron-deficiency anaemia and its effect on worker productivity and activity patterns”, British Medical Journal, 2:1546-1549 (1979).
P. Geisser et al., “Pharmacokinetics of Iron Salts and Ferric Hydroxide-Carbohydrate Complexes”, Arzneimittelforshung/Drug Research, 37(1): 100-104 (1987).
A.F. Goodard et al., “Guidelines for the management of iron deficiency anaemia”, BSG Guidelines in Gastroenterology, 2005.
R.S.J. Harvey et al., “Ferric trimaltol corrects iron deficiency anaemic in patients intolerant of iron”, Aliment Pharmacol. Ther., 12: 845-848 (1998).
H.C. Heinrich, “Bioavailability of Trivalent Iron in Oral Iron Preparations”, Arzneimittelforshung/Drug Research, 25(3): 420-426 (1975).
S. Hercberg et al., “Iron deficiency in Europe”, Public Health Nutrition, 4(2B): 537-545 (2001).
R. Jugdaohsingh et al., “Rapid non-equilibrium aluminum-ligand interactions: studies on the precipitation of aluminum by laser light scattering, ultrafiltration and centrifugation”, J. Inorg. Biochem., 87: 29-35 (2001).
R. Jugdaohsingh et al., “A rapid non-equilibrium critical precipitation assay to assess aluminum-ligand interactions”, Chemical Speciation and Bioavailability, 16(3): 87-96 (2004).
J.P. Kaltwasser et al., “Bioavailability and Therapeutic Efficacy of Bivalent and Trivalent Iron Preparations”, Arzneimittelforshung/Drug Research, 37(1a): 122-129 (1987).
P. Nielsen et al., “Bioavailability of Iron from Oral FErric Polymaltose in Humans”, Arzneimittelforshung/Drug Research, 44(1): 743-748 (1994).
J. Powell et al., “Application of the critical preparation assay to complex samples: aluminum binding capacity of human gastrointestinal fluids”, Chemical Speciation and Bioavailability, 16(3): 97-104 (20040.
F. Smith et al., “Serum Iron Determination Using Ferene Triazine”, Clinical Biochemistry, 17: 306-310 (1984).
B.D. Scholz et al. “Anaemia is associated with reduced productivity of women workers even in less-physically-strenuous tasks”, British Journal of Nutrition, 77(1): 47-57 (1997).
A.F. Hollerman et al., “Luhrbuch der Anorganischen Chemie”, Berlin, Walter de Gruyter, DE, pp. 930-931 (1976).
A.F. Hollerman et al., “Luhrbuch der Anorganischen Chemie”, Berlin, Walter de Gruyter, DE, pp. 929 (1995).
Jerome Rose et al., “Synthesis and Characterization of Carboxylate-FeOOH Nanoparticles (Ferroxanes) and Ferroxane-Derived Ceramics”, Chem. Mater., 14: 621-628 (2002).
Bruggraber Sylvaine Francoise
Faria Nuno Jorge Rodrigues
Pereira Dora Isabel Amaral
Powell Jonathan Joseph
Dann Dorfman Herrell and Skillman, P.C.
Gonzalez Porfirio Nazario
Hagan Patrick J.
Medical Research Council
LandOfFree
Ligand modified poly oxo-hydroxy metal ion materials, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligand modified poly oxo-hydroxy metal ion materials, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand modified poly oxo-hydroxy metal ion materials, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4300524